Congratulations to Sarah McDonald, the inspirational founder of medtech company Baymatob, for being named as one of 2022’s 20 Fiercest Women in Life Sciences by respected US-based Fierce Pharma, from a field of 400 nominees.
One of Alberts Impact Ventures portfolio companies, Alberts is proud to have invested in Baymatob, putting maternal health at the forefront of medical science.
Baymatob’s chief visionary officer, McDonald is a Sydney doctor, engineer and mother who has dedicated the past nine years of her life to developing Oli, a game-changing world-first wearable medical device tackling the leading cause of preventable maternal death, postpartum haemorrhage (PPH).
Alongside CEO Tara Croft, Sarah and her female-dominated, diverse team of 22 people have already seen Oli granted breakthrough device designation from the US Food and Drug Administration (FDA).
Baymatob was also recently announced as one of five companies to join this year’s cohort of the federal government’s prestigious digital health commercialisation program, ANDHealth+.
In March Baymatob completed a successful Series A capital raise of $4.215 million with proceeds helping fund the largest Australian human clinical trial of its medical device, led by Australian Unity’s Future of Healthcare Fund and Global Bio Fund and Alberts Impact Ventures.
Read more on 2022’s Fiercest Women in Life Sciences.
